Amgen’s Nonconformist Position On Biosimilar Payment Policy Reflects Market Strategy

 
• By Cathy Kelly
  
Disruptive innovation Independent leadership concept and individuality as a group of acrobatic jets with one individual jet going in the opposite direction as a business symbol for new thinking. - Illustration
Amgen Charting Its Own Course On Biosimilar Policy
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Biosimilars & Generics